Analysts Set Humacyte, Inc. (NASDAQ:HUMA) PT at $13.71

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been given a consensus recommendation of “Buy” by the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $13.71.

HUMA has been the subject of several recent analyst reports. Benchmark reiterated a “buy” rating on shares of Humacyte in a research note on Thursday, February 27th. D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Wednesday, March 26th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th.

Humacyte Stock Down 2.0 %

Shares of NASDAQ:HUMA opened at $1.46 on Friday. The business has a fifty day simple moving average of $3.43 and a 200 day simple moving average of $4.42. The firm has a market cap of $183.75 million, a P/E ratio of -1.09 and a beta of 1.36. Humacyte has a 12-month low of $1.31 and a 12-month high of $9.97.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.07. The company had revenue of $7.23 million during the quarter, compared to the consensus estimate of $0.64 million. As a group, equities research analysts expect that Humacyte will post -1.27 EPS for the current year.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp grew its holdings in shares of Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after purchasing an additional 1,895,529 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Humacyte in the 3rd quarter worth about $596,000. Thrivent Financial for Lutherans bought a new position in Humacyte in the third quarter worth approximately $712,000. Barclays PLC raised its holdings in shares of Humacyte by 177.6% in the third quarter. Barclays PLC now owns 236,742 shares of the company’s stock valued at $1,288,000 after acquiring an additional 151,458 shares in the last quarter. Finally, Brookstone Capital Management purchased a new stake in shares of Humacyte in the 4th quarter worth approximately $56,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.